Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gentle leg wiggle protect your arteries while you sit?

NCT ID NCT06389149

Knowledge-focused Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests a simple, passive leg movement called LEAP therapy in people with peripheral artery disease (PAD). Participants sit for 2.5 hours with or without the leg movement, and researchers measure blood flow, walking ability, and other health markers. The goal is to see if this easy motion can counteract the harmful effects of prolonged sitting on leg circulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LEAP therapy (passive leg movement)
What this could lead to
If it works, this could point toward a simple way to protect leg blood flow during long periods of sitting for people with peripheral artery disease.
What could go wrong
This is a very small, early-stage study (24 participants) testing a short-term effect, not a treatment. It may not lead to any lasting benefit or change in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Aug 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PAD subjects: * Able to provide written informed consent * 50-85 years of age * Diagnosed with Peripheral Arterial Disease (PAD) Fontaine stage II-III * Women must be postmenopausal (cessation of menses for \> 24 months) * History of exercise-induced claudication * Free of ulcers, gangrene, or necrosis of the foot, Fontaine stage IV PAD Age-matched control subjects: * Able to provide written informed consent * 50-85 years of age * No evidence of peripheral occlusive disease, ankle-brachial index \> 0.90 * Women must be postmenopausal (cessation of menses for \> 24 months) Exclusion Criteria: PAD subjects: * Pain at rest and/or tissue loss from Peripheral Arterial Disease (PAD), Fontaine stage IV PAD * Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma * Limited walking capacity from conditions other than PAD * Have not had a physical exam to assess exercise limitations in the past year * Pregnant or nursing * Kidney disease or type II diabetes mellitus Age-matched control subjects: * Positive diagnosis of Peripheral Arterial Disease (PAD) * Any exercise limitations as determined at last physical exam, at least 1 year prior to study * Have not had a physical exam to assess exercise limitations in the past year * Limited walking capacity from musculoskeletal injury * Pregnant or nursing * Kidney disease or type II diabetes mellitus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral arterial disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

peripheral arterial disease peripheral arterial occlusive disease 1 peripheral vascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral arterial disease Peripheral artery disease Peripheral artery occlusive disease Peripheral vascular disease

Contacts and locations

Locations

  • University of Nebraska - Omaha

    Omaha, Nebraska, 68182, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.